The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes
| Autor: | Yochai Birnbaum, Padma Sathyanarayana, Somasekhar Konduru, Absalon D. Gutierrez, Mandeep Bajaj, Yumei Ye |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Time Factors medicine.drug_class Inflammation Type 2 diabetes Fatty Acids Nonesterified Drug Administration Schedule law.invention Insulin resistance Randomized controlled trial law Diabetes mellitus Internal medicine medicine Humans Hypoglycemic Agents Thiazolidinedione Glycated Hemoglobin Adiponectin Pioglitazone business.industry Body Weight Middle Aged medicine.disease Texas Up-Regulation Lipoxins Endocrinology Treatment Outcome Diabetes Mellitus Type 2 Female Thiazolidinediones medicine.symptom Cardiology and Cardiovascular Medicine business Biomarkers medicine.drug |
| Zdroj: | Atherosclerosis. 223(1) |
| ISSN: | 1879-1484 |
| Popis: | Arachidonic acid-derived eicosanoids (lipoxins and 15-epilipoxins) have a major role in resolution of inflammation. 15-epi-lipoxin A(4) (15-epi-LXA(4)) is a lipid mediator with strong anti-inflammatory and inflammation-resolving effects. We examined the effect of pioglitazone therapy on plasma 15-epi-LXA(4) in patients with type 2 diabetes (T2DM).T2DM patients (Age = 56 ± 2 y, BMI = 33 ± 1.8, HbA1c = 7.8 ± 0.3%) not on thiazolidinedione therapy for at least 12 months were randomized to receive either pioglitazone 15 mg/daily for two months (PIO 15) or pioglitazone 15 mg/day for one month followed by a dose escalation to 30 mg/day for an additional one month (PIO 30).PIO 15 increased plasma 15-epi-LXA(4) levels (0.63 ± 0.06-1.05 ± 0.08 ng/mL, p0.01) and adiponectin levels (6.4 ± 0.3-10.1 ± 0.7 μg/mL, p0.001) and decreased fasting plasma glucose (125 ± 8-106 ± 9 mg/dL, p0.05), free fatty acids (FFA) (414 ± 46-320 ± 38 μmol/l, p0.05) and HOMA-IR (5.3 ± 0.4 to 4.0 ± 0.4, p0.05). Body weight (Δ = 0.2 kg) and HbA1c (7.4 ± 0.2-7.1 ± 0.2%) did not change significantly. PIO 30 treated patients had similar increase in plasma 15-epi-LXA(4) (0.64 ± 0.10-1.08 ± 0.09 ng/mL, p0.01), and decrease in plasma FFA (423 ± 42-317 ± 40 μmol/l, p0.05) despite a greater increase in plasma adiponectin (6.5 ± 0.4-15.5 ± 0.7 ug/mL, p0.001) and a greater reduction in HbA1c (8.7 ± 0.5-7.4 ± 0.3%, p0.01), FPG (159 ± 16-120 ± 10 mg/dL, p0.01), and HOMA-IR (6.6 ± 0.8-4.4 ± 0.4, p0.005). Furthermore, PIO 30 treated patients had a significant increase in body weight (Δ = 1.7 kg, p0.02).In T2DM, low dose pioglitazone (15 mg/day) increases 15-epi-LXA(4) and adiponectin levels in the absence of significant changes in body weight. Dose escalation of pioglitazone to 30 mg/day is associated with a similar increase in 15-epi-LXA(4) despite a greater increase in plasma adiponectin concentrations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect